Literature DB >> 17375084

Optimisation of anti-psychotic therapeutics: a balancing act?

A J Lawrence1.   

Abstract

Schizophrenia is a complex and debilitating disorder. Although effective therapeutic strategies are available, these are not without problems and are not universally efficacious. In this issue of the British Journal of Pharmacology, a trio of papers describe the characterisation of a potential, novel anti-psychotic medication, F15063. This compound combines antagonism of dopamine D(2)-like receptors with agonism at 5-HT(1A) receptors. Based on in vitro and in vivo profiles, the authors suggest that this compound approaches the 'optimal balance' for activity at these receptor systems.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17375084      PMCID： PMC2013954          DOI： 10.1038/sj.bjp.0707164

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  10 in total

Review 1.  Neurobiology of schizophrenia.

Authors:  Christopher A Ross; Russell L Margolis; Sarah A J Reading; Mikhail Pletnikov; Joseph T Coyle
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

2.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Authors:  R Depoortère; L Bardin; A L Auclair; M S Kleven; E Prinssen; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

3.  The economic burden of schizophrenia in the United States in 2002.

Authors:  Eric Q Wu; Howard G Birnbaum; Lizheng Shi; Daniel E Ball; Ronald C Kessler; Matthew Moulis; Jyoti Aggarwal
Journal:  J Clin Psychiatry       Date:  2005-09       Impact factor: 4.384

4.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

Authors:  R Depoortère; A L Auclair; L Bardin; L Bruins Slot; M S Kleven; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

5.  F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.

Authors:  A Newman-Tancredi; M-B Assié; J-C Martel; C Cosi; L Bruins Slot; C Palmier; I Rauly-Lestienne; F Colpaert; B Vacher; D Cussac
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

6.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

7.  Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

Authors:  Robert A Rosenheck; Douglas L Leslie; Jody Sindelar; Edward A Miller; Haiqun Lin; T Scott Stroup; Joseph McEvoy; Sonia M Davis; Richard S E Keefe; Marvin Swartz; Diana O Perkins; John K Hsiao; Jeffrey Lieberman
Journal:  Am J Psychiatry       Date:  2006-12       Impact factor: 18.112

8.  Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia.

Authors:  Richard E Straub; Yuxin Jiang; Charles J MacLean; Yunlong Ma; Bradley T Webb; Maxim V Myakishev; Carole Harris-Kerr; Brandon Wormley; Hannah Sadek; Bharat Kadambi; Anthony J Cesare; Avi Gibberman; Xu Wang; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler
Journal:  Am J Hum Genet       Date:  2002-07-03       Impact factor: 11.025

9.  DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling.

Authors:  J Kirsty Millar; Benjamin S Pickard; Shaun Mackie; Rachel James; Sheila Christie; Sebastienne R Buchanan; M Pat Malloy; Jennifer E Chubb; Elaine Huston; George S Baillie; Pippa A Thomson; Elaine V Hill; Nicholas J Brandon; Jean-Christophe Rain; L Miguel Camargo; Paul J Whiting; Miles D Houslay; Douglas H R Blackwood; Walter J Muir; David J Porteous
Journal:  Science       Date:  2005-11-18       Impact factor: 47.728

10.  A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms.

Authors:  Jeremy Hall; Heather C Whalley; Dominic E Job; Ben J Baig; Andrew M McIntosh; Kathryn L Evans; Pippa A Thomson; David J Porteous; David G Cunningham-Owens; Eve C Johnstone; Stephen M Lawrie
Journal:  Nat Neurosci       Date:  2006-10-29       Impact factor: 24.884
  10 in total
  2 in total

Review 1.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

Authors:  Adrian Newman-Tancredi; Mark S Kleven
Journal:  Psychopharmacology (Berl)       Date:  2011-03-11       Impact factor: 4.530

2.  A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization.

Authors:  Eelke van der Horst; Julio E Peironcely; Adriaan P Ijzerman; Margot W Beukers; Jonathan R Lane; Herman W T van Vlijmen; Michael T M Emmerich; Yasushi Okuno; Andreas Bender
Journal:  BMC Bioinformatics       Date:  2010-06-10       Impact factor: 3.169
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.